jpm_asset_mgmt
  • Products

    Funds

    • Performance & Yields
    • Liquidity
    • Ultra-Short
    • Short Duration

    Solutions

    • Cash Segmentation
    • Separately Managed Accounts
    • Managed Reserves Strategy
  • Insights

    Liquidity Insights

    • Liquidity Insights Overview
    • Audio Commentaries
    • Case Studies
    • Leveraging the Power of Cash Segmentation
    • Cash Investment Policy Statement
    • China Money Market Resource Centre
    • PeerView Survey

    Market Insights

    • Market Insights Overview
    • Eye on the Market
    • Guide to the Markets
    • Market Updates

    Portfolio Insights

    • Portfolio Insights Overview
    • Currency
    • Fixed Income
    • Long-Term Capital Market Assumptions
    • Sustainable Investing
  • Resources
    • MORGAN MONEY
    • Account Management & Trading
    • Multimedia
    • Announcements
  • About us
  • Contact us
Skip to main content
  • English
  • Role
  • Country
  • MORGAN MONEY LOGIN
Search
Menu
CLOSE
Search
You are about to leave the site Close
J.P. Morgan Asset Management’s website and/or mobile terms, privacy and security policies don't apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan Asset Management isn’t responsible for (and doesn't provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan Asset Management name.
CONTINUE Go Back
  1. Home
  2. Insights
  3. Liquidity Insights Overview
  4. Case Studies
  5. AstraZeneca

  • Share
  • LinkedIn Twitter Facebook
  • Email
  • Print
  • Actions
  • LinkedIn Twitter Facebook
    Email Print
Web

AstraZeneca

Case study

Identifying a successful short-term investment solution
A  proactive approach aided AstraZeneca, a global biopharmaceutical company in balancing its longer-term securities with flexible liquidity.

The challenge

Like most corporations, AstraZeneca has a short-term investment policy that weights capital preservation and liquidity above yield. In line with this philosophy, the company historically had a very short-term investment horizon, primarily investing in money market funds (MMFs) and overnight cash deposits. “In times of crisis, such as in 2008, we would go ultra-cautious and invest in shortdated US treasury funds,” explains Alex Fiott, Head of Front Office, Treasury at AstraZeneca.

Although nothing was fundamentally wrong with this approach, Fiott and his colleague Peter Walker-Smith, believed that cash could be managed more actively. They set about reviewing how it segmented its cash and found that much of it could be invested for a longer time horizon, potentially resulting in more yield.

“Being so heavily invested in MMFs that invest in a high concentration of financials meant that AstraZeneca was effectively paying for somebody else’s liquidity,” says Fiott. “This, tied with the changing banking and MMF regulatory landscape, made it a good time to step back and challenge our existing investment policy to see what else we could do. We therefore reached out to our liquidity partners to see what alternative solutions were available.”

The solution

They decided to use tri-party repurchase agreements (repos) and separately managed accounts1 (SMAs) to invest its short-term cash. AstraZeneca chose to use SMAs because of the flexibility they offer. A further benefit was the opportunity for the team to leverage the knowledge and expertise of its fund managers by mandating them to make investments in longer-dated securities on AstraZeneca’s behalf. It was hoped that this would provide incremental returns above those of MMFs, while still retaining the aim of capital preservation and flexible liquidity.

Moving to these products was welcomed by senior management, not least because of the treasury team’s proactive approach. “Given the changing regulatory environment, we were really taking steps to get ahead of the game,” says Fiott. “And because the products we are using fit within the parameters of our existing investment policy, it didn’t take much to persuade the risk committee that this was a positive step to take. The security of capital preservation remained, but our cash worked harder.” It must be noted, however, that adopting these solutions comes with its challenges. Fiott highlights that the documentation and legal work which is needed can put some corporates off. “It can take several months to do this and there is a lot of ancillary work that is required, especially when setting up a tri-party repo agreement,” he observes. That being said, Fiott notes that the benefits have been well worth this effort2. Not only does AstraZeneca have a more diversified portfolio; the tri-party repos and SMAs are yielding 25/30bps over MMFs a year.

Working with an experienced and trusted liquidity partner such as J.P. Morgan Asset Management has been instrumental to AstraZeneca. “J.P. Morgan Asset Management was our partner on this journey from the very beginning,” says Fiott. “Perhaps what is most important is that they always offer us an unbiased view of what is happening in the market and breadth of solutions that are available. This helps lead us to reach best practice, and focus on our actual needs. Their track record and expertise in operating short-dated liquidity funds also instils confidence when outsourcing your investments to them.”

Fiott notes that segmenting the group’s cash and exploring alternative investment vehicles has been a rewarding exercise for AstraZeneca and one that he would recommend to other corporates. Looking forward, the treasury team is also planning to explore what more can be done to refine the existing product solutions in order to diversify further thus continuing a proactive approach to managing liquidity.

1Separately managed accounts create a customised portfolio of securities based on an investor’s particular tolerance for credit and interest rate risk, cash flows, tax status and investment horizon.
2There are also risks that apply to investment services and strategies, which should be reviewed carefully before taking any investment action.

0903c02a81d52c7e

EXPLORE MORE

Case studies

Read about companies with specific cash management challenges and the solutions when they worked with J.P. Morgan Asset Management.

Learn more

MORGAN MONEY

Invest with ease, operational efficiency and effective controls via our state-of-the-art trading and analytics platform.

Learn more
J.P. Morgan Asset Management

  • Investment stewardship
  • About us
  • Contact us
  • Privacy policy
  • Cookie policy
  • Binding corporate rules
  • Sitemap
Decorative
J.P. Morgan

  • J.P. Morgan
  • JPMorgan Chase
  • Chase

READ IMPORTANT LEGAL INFORMATION. CLICK HERE >

The value of investments may go down as well as up and investors may not get back the full amount invested.

Copyright 2021 JPMorgan Chase & Co. All rights reserved.